Tobin Schilke - Dec 31, 2021 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role
CFO
Signature
/s/ Terri McDowell, Attorney-in-Fact
Stock symbol
RVNC
Transactions as of
Dec 31, 2021
Transactions value $
$5,604
Form type
4
Date filed
1/4/2022, 07:58 PM
Previous filing
Dec 17, 2021
Next filing
Feb 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Other $5.6K +404 +0.6% $13.87 68.1K Dec 31, 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan (the "Plan") on December 31,2021 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).